346 related articles for article (PubMed ID: 21962403)
1. Impact of soluble TWEAK and CD163/TWEAK ratio on long-term cardiovascular mortality in patients with peripheral arterial disease.
Urbonaviciene G; Martin-Ventura JL; Lindholt JS; Urbonavicius S; Moreno JA; Egido J; Blanco-Colio LM
Atherosclerosis; 2011 Dec; 219(2):892-9. PubMed ID: 21962403
[TBL] [Abstract][Full Text] [Related]
2. Peripheral artery disease is associated with a high CD163/TWEAK plasma ratio.
Moreno JA; Dejouvencel T; Labreuche J; Smadja DM; Dussiot M; Martin-Ventura JL; Egido J; Gaussem P; Emmerich J; Michel JB; Blanco-Colio LM; Meilhac O
Arterioscler Thromb Vasc Biol; 2010 Jun; 30(6):1253-62. PubMed ID: 20299688
[TBL] [Abstract][Full Text] [Related]
3. Alterations of soluble TWEAK and CD163 concentrations in patients with chronic heart failure.
Ptaszynska-Kopczynska K; Marcinkiewicz-Siemion M; Lisowska A; Waszkiewicz E; Witkowski M; Jasiewicz M; Miklasz P; Jakim P; Galar B; Musial WJ; Kaminski KA
Cytokine; 2016 Apr; 80():7-12. PubMed ID: 26916171
[TBL] [Abstract][Full Text] [Related]
4. The association of high sCD163/sTWEAK ratio with cardiovascular disease in hemodialysis patients.
Rusu CC; Racasan S; Kacso IM; Ghervan L; Moldovan D; Potra A; Patiu IM; Bondor C; Caprioara MG
Int Urol Nephrol; 2015 Dec; 47(12):2023-30. PubMed ID: 26433887
[TBL] [Abstract][Full Text] [Related]
5. Serum sTWEAK concentrations and risk of developing type 2 diabetes in a high cardiovascular risk population: a nested case-control study.
Díaz-López A; Chacón MR; Bulló M; Maymó-Masip E; Martínez-González MA; Estruch R; Vendrell J; Basora J; Díez-Espino J; Covas MI; Salas-Salvadó J
J Clin Endocrinol Metab; 2013 Aug; 98(8):3482-90. PubMed ID: 23760626
[TBL] [Abstract][Full Text] [Related]
6. High serum sCD163/sTWEAK ratio is associated with lower risk of digital ulcers but more severe skin disease in patients with systemic sclerosis.
Kowal-Bielecka O; Bielecki M; Guiducci S; Trzcinska-Butkiewicz B; Michalska-Jakubus M; Matucci-Cerinic M; Brzosko M; Krasowska D; Chyczewski L; Kowal K
Arthritis Res Ther; 2013; 15(3):R69. PubMed ID: 23800379
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of sCD163 and sTWEAK in patients with stable peripheral arterial disease and association with disease severity as well as long-term mortality.
Mrak D; Zierfuss B; Höbaus C; Herz CT; Pesau G; Schernthaner GH
Atherosclerosis; 2021 Jan; 317():41-46. PubMed ID: 33378730
[TBL] [Abstract][Full Text] [Related]
8. Serum levels of CD163 and TWEAK in patients with pulmonary arterial hypertension.
Jasiewicz M; Kowal K; Kowal-Bielecka O; Knapp M; Skiepko R; Bodzenta-Lukaszyk A; Sobkowicz B; Musial WJ; Kaminski KA
Cytokine; 2014 Mar; 66(1):40-5. PubMed ID: 24548423
[TBL] [Abstract][Full Text] [Related]
9. Serum levels of TWEAK and scavenger receptor CD163 in type 1 diabetes mellitus: relationship with cardiovascular risk factors. a case-control study.
Llauradó G; González-Clemente JM; Maymó-Masip E; Subías D; Vendrell J; Chacón MR
PLoS One; 2012; 7(8):e43919. PubMed ID: 22937125
[TBL] [Abstract][Full Text] [Related]
10. Soluble TWEAK and Major Adverse Cardiovascular Events in Patients with CKD.
Fernández-Laso V; Sastre C; Valdivielso JM; Betriu A; Fernández E; Egido J; Martín-Ventura JL; Blanco-Colio LM
Clin J Am Soc Nephrol; 2016 Mar; 11(3):413-22. PubMed ID: 26728587
[TBL] [Abstract][Full Text] [Related]
11. Markers of inflammation in relation to long-term cardiovascular mortality in patients with lower-extremity peripheral arterial disease.
Urbonaviciene G; Frystyk J; Flyvbjerg A; Urbonavicius S; Henneberg EW; Lindholt JS
Int J Cardiol; 2012 Oct; 160(2):89-94. PubMed ID: 21463908
[TBL] [Abstract][Full Text] [Related]
12. Soluble TWEAK is associated with atherosclerotic burden in patients with chronic kidney disease.
Valdivielso JM; Coll B; Martín-Ventura JL; Moreno JA; Egido J; Fernández E; Blanco-Colio LM
J Nephrol; 2013; 26(6):1105-13. PubMed ID: 23475462
[TBL] [Abstract][Full Text] [Related]
13. The CD163-expressing macrophages recognize and internalize TWEAK: potential consequences in atherosclerosis.
Moreno JA; Muñoz-García B; Martín-Ventura JL; Madrigal-Matute J; Orbe J; Páramo JA; Ortega L; Egido J; Blanco-Colio LM
Atherosclerosis; 2009 Nov; 207(1):103-10. PubMed ID: 19473660
[TBL] [Abstract][Full Text] [Related]
14. Reduced sTWEAK and increased sCD163 levels in HIV-infected patients: modulation by antiretroviral treatment, HIV replication and HCV co-infection.
Beltrán LM; Muñoz Hernández R; de Pablo Bernal RS; García Morillo JS; Egido J; Noval ML; Ferrando-Martinez S; Blanco-Colio LM; Genebat M; Villar JR; Moreno-Luna R; Moreno JA
PLoS One; 2014; 9(3):e90541. PubMed ID: 24594990
[TBL] [Abstract][Full Text] [Related]
15. Reduced circulating levels of TWEAK are associated with gestational diabetes mellitus.
Simón-Muela I; Llauradó G; Chacón MR; Olona M; Näf S; Maymó-Masip E; Gil P; de la Flor M; Gonzalez Clemente JM; Vendrell J; Megía A
Eur J Clin Invest; 2015 Jan; 45(1):27-35. PubMed ID: 25443800
[TBL] [Abstract][Full Text] [Related]
16. Serum sCD163 levels are associated with type 2 diabetes mellitus and are influenced by coffee and wine consumption: results of the Di@bet.es study.
Rojo-Martínez G; Maymó-Masip E; Rodríguez MM; Solano E; Goday A; Soriguer F; Valdés S; Chaves FJ; Delgado E; Colomo N; Hernández P; Vendrell J; Chacón MR
PLoS One; 2014; 9(6):e101250. PubMed ID: 24978196
[TBL] [Abstract][Full Text] [Related]
17. Predictive value of soluble haemoglobin scavenger receptor CD163 serum levels for survival in verified tuberculosis patients.
Knudsen TB; Gustafson P; Kronborg G; Kristiansen TB; Moestrup SK; Nielsen JO; Gomes V; Aaby P; Lisse I; Møller HJ; Eugen-Olsen J
Clin Microbiol Infect; 2005 Sep; 11(9):730-5. PubMed ID: 16104988
[TBL] [Abstract][Full Text] [Related]
18. Macrophage serum markers in pneumococcal bacteremia: Prediction of survival by soluble CD163.
Møller HJ; Moestrup SK; Weis N; Wejse C; Nielsen H; Pedersen SS; Attermann J; Nexø E; Kronborg G
Crit Care Med; 2006 Oct; 34(10):2561-6. PubMed ID: 16915112
[TBL] [Abstract][Full Text] [Related]
19. Association of serum adiponectin with risk for cardiovascular events in patients with peripheral arterial disease.
Urbonaviciene G; Frystyk J; Flyvbjerg A; Henneberg EW; Lindholt JS
Atherosclerosis; 2010 Jun; 210(2):619-24. PubMed ID: 20096841
[TBL] [Abstract][Full Text] [Related]
20. Role of the tumour necrosis factor-like weak inducer of apoptosis (TWEAK)/fibroblast growth factor-inducible 14 (Fn14) axis in autoimmune thyroid disease.
Peng S; Yu X; Zhao X; Wang X; Sun X; Han C; Shan Z; Li C; Teng W
Clin Endocrinol (Oxf); 2017 Dec; 87(6):783-790. PubMed ID: 28636775
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
